High-Quality Digital Experiences for ASCO 2021
HIGH-QUALITY DIGITAL EXPERIENCES TO DIFFERENTIATE YOUR BRAND
HOW WE CAN HELP…
Random42 consists of scientists, artists, animators and programmers, who collaborate to effortlessly intertwine the worlds of science, art and technology, producing some of the most impactful scientific imagery, stories and interactive experiences.
With a unique creative team consisting of both 3D artists and interactive developers, Random42 hosts the collaboration necessary to create the highest quality, cutting-edge experiences.
Our team can create a purpose-built app, seamlessly integrating animations and stunning visuals, allowing the user to interact with molecular structures. Rich stimulating imagery promotes deeper engagement and reinforces the scientific story behind the pharmaceutical product.
ASCO is fast approaching, which is why it is important to act now. The ideal time to begin planning for an event like this is at least 3-4 months before – a typical timescale to produce a medical animation (including approvals) is around 12 weeks. If you don’t have 3-4 months in your schedule, there are still options for accelerated production with Random42 without compromising on quality. Please get in touch as soon as possible if this is something you would like to discuss with us.
WHY IS ASCO SO IMPORTANT?
When ASCO was established over 50 years ago, the founding members wanted an annual meeting to share the latest information about the treatment of cancer as a top priority. This was back in a time when oncology was not yet recognized as a medical specialty.
Since then, ASCO has grown to become one of the most significant biopharma conventions in the industry and one of the largest gatherings of medical professionals in the world. It brings together more than 30,000 doctors, scientists, public officials, patient advocates, investors, and life science executives.
Thousands of scientific abstracts are released in May ahead of the meeting, giving investors an early opportunity to investigate the latest in the oncology drug development field. Many companies will keep their most significant data under wraps, unveiling them as ground-breaking presentations during the conference.